Emcure Pharmaceuticals financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹2,580cr+22.8% on Q1 FY26
Net profit
₹292cr+36.2% on Q1 FY26
EBITDA margin
20.6%+0.8 pts on Q1 FY26
EPS
₹15.50+41.9% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue2,5802,101+22.8%
EBITDA532417+27.8%
EBITDA margin20.6%19.8%+0.8 pts
Profit before tax394291+35.3%
Net profit292215+36.2%
EPS₹15.50₹10.92+41.9%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹2,580 crNet profit₹292 crNet margin11.3%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
35,548——
137137232
26.626.6195
1,2041,204732
36,642——
9,6839,2047,896
—+16.6%—
1,9801,8651,474
20.5%20.3%18.7%
1,5551,4501,090
1,019941707
10.5%10.2%9.0%
₹53.35₹48.76₹35.94
—+35.7%—
—944852
—−548−407
396396445
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

EMCURE₹1,875.00

Emcure Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersMANKINDALKEMTORNTPHARMERISGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹35,548 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization——35,548.1
- Cash, Equiv & ST Investments231.6136.7136.7
+ Minority Interest195.426.626.6
+ Total Debt731.71,204.11,204.1
Enterprise Value——36,642.2
Revenue7,896.09,203.59,683.5
Growth %, YoY—+16.6—
EBITDA1,474.41,864.51,980.3
Margin %18.6720.2620.45
EBIT1,090.31,449.51,555.2
Net Income707.5941.31,019.0
Margin %8.9610.2310.52
EPS, Adj (current shares)35.9448.7653.35
Growth %, YoY—+35.7—
Cash from Operations851.7943.5—
Capital Expenditures-406.9-547.7—
Free Cash Flow444.8395.9395.9
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Emcure Pharmaceuticals financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Emcure Pharmaceuticals (NSE: EMCURE) had a market capitalisation of ₹35,376 crore at the 29 October 2026 close (₹1,865.00 a share), a PE ratio of 35.0 on the last four quarters' profit and a price-to-book ratio of 7.15. In FY26 its consolidated net profit attributable to shareholders was ₹924 crore on revenue of ₹9,204 crore; in Q1 FY27 (April–June 2026) it was ₹294 crore, up 42.1% year on year. Its debt-to-equity ratio was 0.24 on 31 March 2026. Promoters held 77.82% of the shares on 30 September 2026.

Share price used
₹1,865.00 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Emcure Pharmaceuticals at a glance · consolidated

Market cap
₹35,376 Crat ₹1,865.00 · 29 Oct close
PE ratio (last 4 quarters)
35.038.3 on FY26 profit
Price to book (PB)
7.15book value ₹260.96 a share
ROE (FY26)
19.7%ROCE 25.7%
Debt to equity
0.24net debt ₹1,057 Cr
Promoter holding
77.82%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.19%₹3.60 a share in 12 months
Net worth
₹4,950 Cr+11.3% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹396 Cr−11.0% vs FY25

Questions

What is the Emcure Pharmaceuticals PE ratio today?

Emcure Pharmaceuticals' PE ratio is 35.0 at the 29 October 2026 close (₹1,865.00 a share): a market capitalisation of ₹35,376 crore divided by consolidated net profit attributable to shareholders of ₹1,011 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹924 crore) it is 38.3.

What is the Emcure Pharmaceuticals PB ratio (price to book value)?

Emcure Pharmaceuticals' price-to-book (PB) ratio is 7.15 at the 29 October 2026 close: a market capitalisation of ₹35,376 crore divided by shareholders' equity (book value) of ₹4,950 crore on 31 March 2026. That is a book value of ₹260.96 per share against a share price of ₹1,865.00.

What is the Emcure Pharmaceuticals ROE and ROCE?

In FY26, Emcure Pharmaceuticals' return on equity (ROE) was 19.7% and its return on capital employed (ROCE) was 25.7%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).

What is the Emcure Pharmaceuticals market cap?

Emcure Pharmaceuticals' market capitalisation was ₹35,376 crore at the 29 October 2026 close: 18.97 crore shares at ₹1,865.00 each.

Is Emcure Pharmaceuticals debt free?

No. Emcure Pharmaceuticals had borrowings of ₹1,204 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.24. Its cash and current investments were ₹148 crore, so its net debt was ₹1,057 crore.

What is the Emcure Pharmaceuticals dividend in 2026 and its record date?

In 2026, Emcure Pharmaceuticals has declared one dividend: ₹3.60 with record date 4 September 2026.

What is the Emcure Pharmaceuticals debt to equity ratio?

Emcure Pharmaceuticals' debt-to-equity ratio was 0.24 on 31 March 2026: borrowings of ₹1,204 crore against total equity of ₹4,977 crore. A year earlier, on 31 March 2025, it was 0.16.

What is the Emcure Pharmaceuticals net worth?

Emcure Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹4,950 crore on 31 March 2026, up 11.3% from ₹4,446 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹35,376 crore at the 29 October 2026 close.

What is the Emcure Pharmaceuticals book value per share?

Emcure Pharmaceuticals' book value per share was ₹260.96 on 31 March 2026: shareholders' equity of ₹4,950 crore divided by the 18.97 crore shares in issue, up 11.2% from ₹234.65 a year earlier. The share price at the 29 October 2026 close was ₹1,865.00.

What is the Emcure Pharmaceuticals EPS?

Emcure Pharmaceuticals' basic earnings per share (EPS) were ₹48.77 in FY26, against ₹36.43 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹53.35.

What is the Emcure Pharmaceuticals revenue and profit in FY26?

In FY26 (April 2025–March 2026), Emcure Pharmaceuticals' consolidated net profit attributable to shareholders was ₹924 crore, up 35.7% from ₹681 crore in FY25, on revenue from operations of ₹9,204 crore (up 16.6%).

When are the Emcure Pharmaceuticals next results?

Emcure Pharmaceuticals will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.

What is the Emcure Pharmaceuticals dividend yield?

Emcure Pharmaceuticals' dividend yield is 0.19% at the 29 October 2026 close: dividends of ₹3.60 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,865.00. They were ₹3.60 on 4 September 2026.

What is the Emcure Pharmaceuticals promoter holding?

Promoters held 77.82% of Emcure Pharmaceuticals on 30 September 2026, down 0.01 percentage points from 77.83% the previous quarter and down 0.06 percentage points from 77.88% a year earlier, according to the shareholding pattern filed with NSE.

What is the Emcure Pharmaceuticals free cash flow?

In FY26, Emcure Pharmaceuticals generated ₹944 crore of cash from operations and spent ₹548 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹396 crore. In FY25 it was ₹445 crore.

What is the Emcure Pharmaceuticals shareholding pattern?

On 30 September 2026, Emcure Pharmaceuticals' shares were held by promoters 77.82%, foreign portfolio investors (FII/FPI) 4.94%, domestic institutions (DII) 8.49% (including mutual funds at 7.05%) and retail and other non-institutional investors 8.75%. Over the year, FII holding was up 1.65 percentage points from 3.29% and DII holding was up 4.12 percentage points from 4.37%.

How does Emcure Pharmaceuticals compare with its peers?

On FY26 consolidated figures, against Mankind Pharma, Alkem Laboratories and Torrent Pharma: Emcure Pharmaceuticals' operating margin of 15.8% is the lowest of the four (Mankind Pharma 19.1%, Alkem Laboratories 17.8%, Torrent Pharma 24.6%; peer average 20.5%); its return on equity of 19.7% is the second highest of the four (Mankind Pharma 12.5%, Alkem Laboratories 17.8%, Torrent Pharma 27.1%; peer average 19.1%).

How does the Emcure Pharmaceuticals PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Emcure Pharmaceuticals' PE ratio is 38.3, the third highest of the four: Mankind Pharma 53.3, Alkem Laboratories 26.4 and Torrent Pharma 80.5, a peer average of 53.4. Each is the company's market capitalisation at that price divided by its FY26 net profit.

What are the Emcure Pharmaceuticals latest quarterly results?

Emcure Pharmaceuticals' latest results are for Q1 FY27 (April–June 2026), filed on 6 August 2026: consolidated net profit attributable to shareholders ₹294 crore, up 42.1% from ₹207 crore in Q1 FY26; revenue from operations ₹2,580 crore, up 22.8% year on year.

Emcure Pharmaceuticals vs Mankind Pharma: how do they compare?

In FY26, Emcure Pharmaceuticals earned net profit attributable to shareholders of ₹924 crore on revenue of ₹9,204 crore, against ₹1,913 crore on ₹14,278 crore for Mankind Pharma. Emcure Pharmaceuticals' operating margin was 15.8% (Mankind Pharma 19.1%) and its return on equity 19.7% (Mankind Pharma 12.5%). At the 29 October 2026 close, Emcure Pharmaceuticals' market capitalisation was ₹35,376 crore against ₹1,01,982 crore for Mankind Pharma, and its PE ratio on FY26 profit 38.3 against 53.3.

Where do these Emcure Pharmaceuticals figures come from?

From Emcure Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.